Logo image of BDTX

BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Fundamental Analysis

USA - NASDAQ:BDTX - US09203E1055 - Common Stock

3.89 USD
+0.16 (+4.29%)
Last: 10/3/2025, 8:24:52 PM
3.87 USD
-0.02 (-0.51%)
Pre-Market: 10/6/2025, 4:03:04 AM
Fundamental Rating

4

Overall BDTX gets a fundamental rating of 4 out of 10. We evaluated BDTX against 536 industry peers in the Biotechnology industry. While BDTX has a great health rating, its profitability is only average at the moment. BDTX has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year BDTX was profitable.
In the past year BDTX had a positive cash flow from operations.
BDTX had negative earnings in each of the past 5 years.
BDTX had a negative operating cash flow in each of the past 5 years.
BDTX Yearly Net Income VS EBIT VS OCF VS FCFBDTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of BDTX (8.68%) is better than 93.10% of its industry peers.
BDTX has a Return On Equity of 10.89%. This is amongst the best in the industry. BDTX outperforms 93.28% of its industry peers.
Looking at the Return On Invested Capital, with a value of 2.48%, BDTX belongs to the top of the industry, outperforming 90.86% of the companies in the same industry.
Industry RankSector Rank
ROA 8.68%
ROE 10.89%
ROIC 2.48%
ROA(3y)-55.71%
ROA(5y)-47.65%
ROE(3y)-77.69%
ROE(5y)-63.81%
ROIC(3y)N/A
ROIC(5y)N/A
BDTX Yearly ROA, ROE, ROICBDTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

BDTX has a Profit Margin of 20.63%. This is amongst the best in the industry. BDTX outperforms 94.59% of its industry peers.
With an excellent Operating Margin value of 6.72%, BDTX belongs to the best of the industry, outperforming 91.04% of the companies in the same industry.
Industry RankSector Rank
OM 6.72%
PM (TTM) 20.63%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDTX Yearly Profit, Operating, Gross MarginsBDTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, BDTX has more shares outstanding
The number of shares outstanding for BDTX has been increased compared to 5 years ago.
There is no outstanding debt for BDTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BDTX Yearly Shares OutstandingBDTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
BDTX Yearly Total Debt VS Total AssetsBDTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of 1.67, we must say that BDTX is in the distress zone and has some risk of bankruptcy.
BDTX has a better Altman-Z score (1.67) than 64.18% of its industry peers.
There is no outstanding debt for BDTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 1.67
ROIC/WACCN/A
WACCN/A
BDTX Yearly LT Debt VS Equity VS FCFBDTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

BDTX has a Current Ratio of 8.73. This indicates that BDTX is financially healthy and has no problem in meeting its short term obligations.
BDTX has a better Current ratio (8.73) than 76.49% of its industry peers.
A Quick Ratio of 8.73 indicates that BDTX has no problem at all paying its short term obligations.
BDTX has a Quick ratio of 8.73. This is in the better half of the industry: BDTX outperforms 76.49% of its industry peers.
Industry RankSector Rank
Current Ratio 8.73
Quick Ratio 8.73
BDTX Yearly Current Assets VS Current LiabilitesBDTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

2

3. Growth

3.1 Past

BDTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 115.33%, which is quite impressive.
EPS 1Y (TTM)115.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BDTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.93% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y128.61%
EPS Next 2Y15.07%
EPS Next 3Y5.89%
EPS Next 5Y11.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BDTX Yearly Revenue VS EstimatesBDTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
BDTX Yearly EPS VS EstimatesBDTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 16.91, the valuation of BDTX can be described as correct.
Based on the Price/Earnings ratio, BDTX is valued cheaply inside the industry as 95.52% of the companies are valued more expensively.
BDTX is valuated rather cheaply when we compare the Price/Earnings ratio to 27.86, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for BDTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 16.91
Fwd PE N/A
BDTX Price Earnings VS Forward Price EarningsBDTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of BDTX indicates a rather cheap valuation: BDTX is cheaper than 97.57% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 12.39
EV/EBITDA -6.77
BDTX Per share dataBDTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.13
PEG (5Y)N/A
EPS Next 2Y15.07%
EPS Next 3Y5.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BDTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLACK DIAMOND THERAPEUTICS I

NASDAQ:BDTX (10/3/2025, 8:24:52 PM)

Premarket: 3.87 -0.02 (-0.51%)

3.89

+0.16 (+4.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners78.76%
Inst Owner Change0%
Ins Owners0.59%
Ins Owner Change0.22%
Market Cap221.50M
Analysts86.15
Price Target10 (157.07%)
Short Float %12.65%
Short Ratio7.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2222.91%
Min EPS beat(2)24.48%
Max EPS beat(2)4421.34%
EPS beat(4)4
Avg EPS beat(4)1121.29%
Min EPS beat(4)12.77%
Max EPS beat(4)4421.34%
EPS beat(8)8
Avg EPS beat(8)569.11%
EPS beat(12)12
Avg EPS beat(12)381.81%
EPS beat(16)16
Avg EPS beat(16)289.6%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.39%
PT rev (3m)-8.13%
EPS NQ rev (1m)-3.94%
EPS NQ rev (3m)3.29%
EPS NY rev (1m)14.3%
EPS NY rev (3m)863.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)50%
Valuation
Industry RankSector Rank
PE 16.91
Fwd PE N/A
P/S 3.16
P/FCF 12.39
P/OCF 12.39
P/B 1.67
P/tB 1.67
EV/EBITDA -6.77
EPS(TTM)0.23
EY5.91%
EPS(NY)-0.86
Fwd EYN/A
FCF(TTM)0.31
FCFY8.07%
OCF(TTM)0.31
OCFY8.07%
SpS1.23
BVpS2.33
TBVpS2.33
PEG (NY)0.13
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 8.68%
ROE 10.89%
ROCE 3.15%
ROIC 2.48%
ROICexc 55.06%
ROICexgc 55.06%
OM 6.72%
PM (TTM) 20.63%
GM N/A
FCFM 25.53%
ROA(3y)-55.71%
ROA(5y)-47.65%
ROE(3y)-77.69%
ROE(5y)-63.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 353.99%
Profit Quality 123.78%
Current Ratio 8.73
Quick Ratio 8.73
Altman-Z 1.67
F-Score9
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)14.94%
Cap/Depr(5y)323.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)115.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.22%
EPS Next Y128.61%
EPS Next 2Y15.07%
EPS Next 3Y5.89%
EPS Next 5Y11.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y105.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year117.97%
EBIT Next 3Y3.46%
EBIT Next 5Y-2.01%
FCF growth 1Y124.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y124.55%
OCF growth 3YN/A
OCF growth 5YN/A